Revance Therapeutics, Inc., a Delaware corporation, recently completed a significant merger transaction with Crown Laboratories, Inc. The completion of this merger marks a pivotal moment in the company’s history and sets the stage for new opportunities and growth.
The merger began with the signing of the Agreement and Plan of Merger on December 7, 2024, and progressed through various important steps until the finalization on February 6, 2025. As detailed in the 8-K SEC Filing submitted by Revance Therapeutics, the transaction involved multiple supplemental agreements, tender offers, and regulatory notifications.
Furthermore, the transaction involved Crown Laboratories acquiring all outstanding shares of Revance Therapeutics, excluding certain exempt shares, at a price of $3.65 per share in cash. The offer was well received, with approximately 82% of the company’s outstanding shares being tendered and accepted for payment by Merger Sub, an affiliate of Crown Laboratories.
Following the completion of the offer, the merger progressed under the terms outlined in the Agreement and Plan of Merger. This resulted in Revance becoming a wholly-owned subsidiary of Crown Laboratories. The completion of this transaction triggered fundamental changes in financial obligations outlined in the Indenture, providing holders of 2027 Convertible Notes with specific rights and options.
In line with the merger, Revance notified The Nasdaq Global Select Market and requested the delisting of its shares. The trading of shares was suspended post-closure of the transaction, and Revance intends to terminate its registration under the Securities Exchange Act of 1934.
Furthermore, with the change in control due to the merger, there were significant departures and appointments within the company’s leadership. Directors and officers were restructured, aligning with the terms of the merger agreement. Additionally, Revance’s certificate of incorporation and bylaws underwent amendments and restatements in line with the merger.
The completion of the merger was officially announced by Crown Laboratories, solidifying its strategic expansion into the aesthetics and skincare market. Crown aims to leverage Revance’s innovative offerings to bolster its position as a leading player in the industry.
Overall, the successful merger between Revance Therapeutics and Crown Laboratories marks a transformative event for both companies, paving the way for synergies and growth in the aesthetics and skincare sector.
For more information on the merger and the companies involved, interested parties can refer to the official documentation filed with the Securities and Exchange Commission.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Revance Therapeutics’s 8K filing here.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Further Reading
- Five stocks we like better than Revance Therapeutics
- What Are Growth Stocks and Investing in Them
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- What Are Earnings Reports?
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
